A kind of polypeptide pro-infection agent

A reagent and sequence technology, applied in the fields of peptides, genetic material components, gene therapy, etc., can solve the problem of low infection efficiency of lentiviral vector system

Active Publication Date: 2017-07-21
2 Cites 0 Cited by

AI-Extracted Technical Summary

Problems solved by technology

[0003] In order to solve the problem of low infection efficiency of the retroviral vector system and the lentiviral vector system in the prior art, the present invention provides a reagent for promo...
View more


The invention relates to a polypeptide with HIV infection promoting ability. The HIV infection promoting polypeptide comprises a peptide sequence, containing a terminal C peptide of near extramembrane fragment MPER fragment of an HIV-1 envelope protein GP41. The polypeptide infection promoting agent provided by the invention has significant activity in promoting envelope viral infection, and shows activity superior to that of a common infection promoting agent DEAE at a cellular level. Therefore, the polypeptide infection promoting agent plays an important role in the development of retroviral or lentiviral gene therapy.

Application Domain

Genetic material ingredientsPeptides +1

Technology Topic

PeptideCellular level +7


  • A kind of polypeptide pro-infection agent
  • A kind of polypeptide pro-infection agent
  • A kind of polypeptide pro-infection agent


  • Experimental program(4)

Example Embodiment

[0018] Example 1
[0019] Peptide Design
[0020] Table 1
[0022] Characterization of pro-infectious activity
[0023] figure 1 Comparison of pro-infection activities of MPER, NK13 and QW13.

Example Embodiment

[0024] Example 2
[0025] Peptide Design
[0026] Table 2
[0027] name describe sequence sequence listing NK13 C-terminal polypeptide of MPER region Ac-NWFDITNWLWYIK SEQ ID NO:1 NK16 NK13-derived peptides Ac-NWFDITNWLWYIKKKK SEQ ID NO:2
[0028] Characterization of pro-infectious activity
[0029] figure 2 Comparison of pro-infection activities of NK16 and NK13.
[0030] Compared with the activity of commonly used pro-infection reagents
[0031] image 3 Comparison of the pro-infection activity of NK16 and DEAE dextran at different infection times.
[0032] Application to other enveloped virus infections
[0033] Figure 4 GFP fluorescence flow cytometric analysis of Hela cells infected with FIV/VSV-G.

Example Embodiment

[0034] Example 3
[0035] Figure 5 Pro-infection activity of NK16 under different ionic strength conditions.
[0036] Image 6 Pro-infection activity of NK16 at different pH conditions.


no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products